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 1 year 2 years 3 years 4 years 5 years 
Death 
ARP 177 134 106 76 48 













WHO clinical stage 3 or 4 
ARP 171 128 100 69 41 













CD4 count < 200/mm3  
   
ARP 175 127 94 66 40 













Any outcome  
   
ARP 169 120 88 62 37 













ARP: at-risk patients ; n: number of patients who reached the outcome ; CI: confidence interval 
CD4 count < 200/mm3
DeathDeath 
CD4 count < 2 0/ m3
WHO clinical stage 3 or 4
Any of the three outcomes
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 1 year 2 years 3 years 4 years 5 years 
HIV-1 DNA ✝  3log10 copies/106 PBMCs 
ARP 90 71 57 41 25 













HIV-1 DNA > 3log10 copies/106 PBMCs 
ARP 79 49 31 21 12 













ARP: at-risk patients ; n: number of patients who reached the outcome ; CI: confidence interval
            HIV-DNA ✞  3log10 copies/106 PBMC HIV-DNA > 3log10 copies/106 PBMC
p < 0.001 
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 1 year 2 years 3 years 4 years 5 years 
CD4 > 350/mm3 
ARP 129 101 74 52 33 













CD4 ✝  350/mm3 
ARP 40 19 14 10 4 













ARP: at-risk patients ; n: number of patients who reached the outcome ; CI: confidence interval
P<0.001 
 










































 1 year 2 years 3 years 4 years 5 years 
HIV-1 RNA ✝  5log10 copies/ml 
ARP 124 99 75 54 34 













HIV-1 RNA > 5log10 copies/ml 
ARP 32 19 13 8 3 













ARP: at-risk patients ; n: number of patients who reached the outcome ; CI: confidence interval 
 
HIV-RNA > 5log10 copies/mlHIV-RNA ✞  5log10 copies/ml
p = 0.055 
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